European Medicines Agency recommends seven new medicines

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines at its March meeting, it has been announced. The new medicines accepted include one advanced therapy medicinal product (ATMP), a medicine reviewed under the EMA’s accelerated assessment scheme and a pandemic flu vaccine. The treatments accepted include: Strimvelis, a new gene therapy designed to treat patients with adenosine-deaminase-deficient severe combined immunodeficiency (ADA-SCID), who have no matching donor for a stem cell transplant. Strimvelis has an orphan designation and is an ATMP Darzalex (daratumumab) for the treatment of relapsed and refractory multiple myeloma. Daratumumab